NCT05626569View on ClinicalTrials.gov

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 10, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2026

Conditions
Esophageal Squamous Cell CarcinomaOligometastatic Disease
Interventions
DRUG

PD-1 combined with SBRT

Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.

Trial Locations (1)

510000

RECRUITING

Mian Xi, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER